RxDoctor Payments Data

David Skolnick, MD

Cardiovascular Disease · Kansas City, MONPI 1194774356

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $32,750 of the $44,398 with a category attached, or 73.8%. 7 manufacturers reported payments, led by Abbott at 52.5% of the total. Reporting peaked in 2021 at $12,649 and has fallen 96.4% since, to $461 in 2025. Among cardiovascular disease clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$44,398in general payments, 2019–2025

Across 101 payments — averaging $439.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$23K
  • Medtronic$17K
  • Edwards Lifesciences$3K
  • Boston Scientific$687
  • Philips North America LLC$150
  • Lantheus Medical Imaging, Inc.$112
  • plus $47 from 1 others

What the payments were for

  • Consulting fees$2,5006%
  • Speaking & faculty fees$32,75074%
  • Travel & lodging$4,98211%
  • Food & beverage$4,1669%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,398 in reported general payments places this provider in the 90th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$120,483
Medicare patients
1,282
Services billed
1,937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban299$327,064
JardianceEmpagliflozin174$226,123
XareltoRivaroxaban49$62,624
EntrestoSacubitril/Valsartan34$43,823
Repatha SureclickEvolocumab19$23,016
OzempicSemaglutide19$22,507
WegovySemaglutide12$17,881
Ezetimibe108$3,118
Metoprolol Succinate261$2,707
Atorvastatin Calcium357$2,596
Flecainide Acetate40$2,457
Diltiazem 24hr Er (Cd)Diltiazem Hcl76$2,423
Rosuvastatin Calcium189$1,636
Telmisartan49$1,545
Losartan Potassium169$1,353

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →